Cervical Cancer

KEYNOTE A18: Pembrolizumab Plus Chemoradiotherapy for High-Risk Locally Advanced Cervical Cancer

Pembrolizumab combined with chemoradiotherapy and then continued post-chemoradiotherapy demonstrates significant improvements in progression-free survival compared to chemoradiotherapy alone

CALLA: Durvalumab versus placebo with chemoradiotherapy

Durvalumab concurrent with chemoradiotherapy was well tolerated but did not significantly improve progression-free survival compared to placebo in a biomarker-unselected all-comers population for locally advanced cervical cancer

SHAPE Trial: Simple versus Radical Hysterectomy in Women with Low-Risk Cervical Cancer

Simple hysterectomy is not inferior to radical hysterectomy in terms of the 3-year incidence of pelvic recurrence and presents a lower risk of urinary complications.

Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer (KEYNOTE-826)

Pembrolizumab significantly improves PFS and OS in PD-L1–positive persistent, recurrent, or metastatic cervical cancer patients when added to standard chemotherapy, with or without bevacizumab, maintaining a manageable safety profile.

Adenoma Malignum

Mini-Tutorial on Adenoma Malignum

BEATcc: Atezolizumab added to Cis/Taxol/Bev in recurrent/metastatic cervical cancer

Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc)

EORTC-55994 and Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer

EORTC and the trial from TATA memorial. Is neoadjuvant chemotherapy and surgery an alternative to chemoradiation in locally advanced cervical cancer?

DESTINY-PanTumor02

Phase II study evaluating the role of HER2-directed ADC Trastuzumab deruxtecan (T-DxD)

Para-aortic Lymph Node Dissection Prior to Radiation Therapy

Do we need to surgically remove para-aortic lymph nodes before radiation therapy?

OUTBACK Trial: Chemotherapy after Chemoradiation

OUTBACK trial